Randomized trial Early signal 30 Japanese adults aged 50 to 80 with mild cognitive impairment; 15 per group
Lion's Mane dry powder and mild cognitive impairment: small randomized trial
Thirty adults with mild cognitive impairment were randomized to Lion's Mane dry-powder tablets or placebo for 16 weeks. The Lion's Mane group had statistically higher cognitive-scale scores than placebo at weeks 8, 12, and 16, but the published abstract gives no effect size or confidence interval. Scores fell significantly during the four weeks after treatment stopped. This is an early human signal, not evidence that Lion's Mane prevents dementia or produces lasting benefit.
- What was studied
- Twelve 250 mg tablets per day, each containing 96% Yamabushitake dry powder, for 16 weeks
- Setting
- Studied alone
- Why it ranks here
- The placebo-controlled design is useful, but 15 people per arm and one cognitive scale cannot provide a stable or broadly generalizable estimate.
Limits and cautions
- Only 30 participants were randomized, leaving the estimate vulnerable to chance and baseline imbalance.
- The publisher abstract reports statistical significance but not the between-group effect size, variance, confidence interval, attrition, or allocation details; no numerical benefit claim is supportable from the accessible source.
- Scores declined four weeks after stopping, so persistence of any effect was not established.
- The study used one Japanese cognitive screening scale and one specific dry-powder tablet regimen; it does not establish equivalence to extracts, mycelium products, or other retail supplements.
- PubMed lists the first author's affiliation as the Mushroom Laboratory of Hokuto Corporation. Affiliations for the other authors, funding sources, and conflict-of-interest disclosures could not be verified from the sources reviewed (the PubMed record and the accessible publisher abstract); this does not mean they are absent.
Lion's Mane products are not FDA-approved to prevent or treat mild cognitive impairment, dementia, or another medical condition.
Randomized trial Early signal 48 healthy Japanese adults aged 60 to 85 were randomized; 47 completed (placebo 14, Y10M 16, C5304 17)
Two Maitake strains produced different cognitive results in a small randomized trial
Forty-eight healthy older adults were randomized and 47 completed an 18-week trial. Y10M differed from placebo on adjusted post-intervention MoCA-J score (p=0.045) and MoCA-J change (p=0.040); C5304 did not. Neither strain differed from placebo on MMSE or HDS-R. No participant discontinued because of an adverse effect. This small, manufacturer-funded study does not establish dementia prevention or a general Maitake effect.
- What was studied
- Bread containing 50 g per day of fresh Maitake strain Y10M or C5304, compared with Maitake-free placebo bread, for 18 weeks
- Setting
- Studied alone
- Why it ranks here
- Randomization and active strain comparison strengthen the design, while the small groups, multiple cognitive outcomes, and a result seen for only one strain make replication essential.
Limits and cautions
- The three completion groups were small (14, 16, and 17), efficacy used a per-protocol analysis, and multiple cognitive, immune, and laboratory outcomes leave a meaningful risk of chance findings.
- The favorable cognitive result was strain-specific: C5304 did not differ from placebo on MoCA-J.
- Reported mean MoCA-J scores fell in the placebo group (26.9 to 25.9) while rising in the Y10M group (26.2 to 27.3), so the between-group difference reflects both changes, not improvement in the Y10M group alone. The paper's p-values come from baseline-adjusted ANCOVA models.
- Participants were healthy older Japanese adults; the trial did not enroll people with dementia or show prevention of cognitive decline.
- YUKIGUNI FACTORY funded the study, manufactured the Maitake test foods, and employed two authors; the paper states that the sponsor did not influence data collection or analysis.
- The study population was geographically restricted, diets were not controlled, genetic and other lifestyle factors were not analyzed, immune assessment was limited to natural-killer cells, and the authors could not explain the strain difference.
Maitake products are not FDA-approved to prevent or treat cognitive impairment, dementia, or another medical condition.
Preclinical study Early signal Three groups of 12 mice: wild-type, untreated APP/PS1, and cordycepin-treated APP/PS1
Cordycepin changed microglial metabolism and memory behavior in an Alzheimer's mouse model
Purified cordycepin changed memory behavior and tissue markers in APP/PS1 mice. Experiments in BV2 and primary microglial cells linked the response to increased glycolysis through HKII and increased PDH-mediated oxidative phosphorylation through PDK2. The paper describes HKII and PDK2 as potential targets and notes that binding hypotheses need further verification. This animal-and-cell study does not demonstrate human treatment efficacy or support claims for whole Cordyceps supplements.
- What was studied
- Purified cordycepin at 10 mg/kg/day by gavage for four weeks; not a Cordyceps mushroom supplement
- Setting
- Studied alone
- Why it ranks here
- The study combines behavioral and mechanistic assays, but it remains one small animal experiment using purified cordycepin and has no human clinical outcome.
Limits and cautions
- The main efficacy experiment used 36 mice, and several tissue assays used only three animals per group.
- APP/PS1 mouse behavior and induced cell models do not establish efficacy or safety in humans with Alzheimer's disease.
- The intervention was purified cordycepin, not Cordyceps militaris, Ophiocordyceps sinensis, a fermentation product, or a retail supplement.
- The paper identifies HKII and PDK2 as potential molecular targets using localization, inhibitor, and metabolic assays; the proposed direct binding modes are hypotheses that the authors state require further verification.
- The authors reported no conflict of interest and public research funding; those statements do not substitute for independent replication.
Cordycepin and Cordyceps supplements are not FDA-approved to prevent or treat Alzheimer's disease or cognitive impairment.